Biomotion Sciences

The momentum for this stock is not very good. Biomotion Sciences is not a good growth stock. Tradey thinks it is not wise to invest in Biomotion Sciences.
Log in to see more information.
SLXN Fundamental Data by TradingView

News

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Business Wire Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for...\n more…